← Eichor
Study identifier: NCT07193654 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread

Condition: Glioblastoma (GBM)  ·  Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

PhasePhase 2
Planned participants38
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn if a combined treatment approach can treat glioblastoma (GBM) with ventricular invasion or meningeal metastasis in adults. The main questions it aims to answer are: Does the combined treatment of radical radiotherapy, the Stupp regimen (oral temozolomide), and intrathecal injection of thiotepa improve progression-free survival compared to standard treatment alone? Does the combined treatment improve overall survival compared to standard treatment alone? Participants will: * Undergo maximal surgical resection of the tumor; * Receive radical radiotherapy; * Take oral temozolomide according to the Stupp regimen; * Receive intrathecal injections of thiotepa。

This description comes directly from the study's public registry record.

Talk to the study team

Ting Zhang, phD.  ·  +86-571-87783521  ·  zezht@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

2nd Affiliated Hospital, School of MedicineHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07193654